Trinity Biotech TRIB - オプションチェーン

Trinity Biotech PLC ([symbol]) オプションチェーン

オプションコール

行使価格	売値	最終取引
2.50	0.95	-
5.00	1.00	-
7.50	1.00	-

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

オプションプット

行使価格	買値	売値	中間価格	最終取引
2.50	1.55	2.50	2.025	-
5.00	2.05	6.80	4.425	-
7.50	4.50	9.30	6.90	-

銘柄コード	株価	出来高
CIITTianci International Inc	US$ 0.988 (101.63%)	23.98M
ADTXAditxt Inc	US$ 0.0284 (47.92%)	168.83M
ORISOriental Rise Holdings Ltd	US$ 3.40 (40.50%)	2.98M
GDCGD Culture Group Ltd	US$ 0.0246 (21.18%)	124.4M
FBLAFB Bancorp Inc	US$ 16.99 (16.93%)	2
NXTSNexentis Techgnologies Inc	US$ 6.9163 (-46.80%)	199.77k
WHLRWheeler Real Estate Investment Trust Inc	US$ 2.45 (-35.53%)	12.82k
WETOWetour Robotics Ltd	US$ 0.8188 (-28.80%)	1.09k
KIDZKIDZ AI Inc	US$ 1.07 (-25.17%)	66.43k
TNONTenon Medical Inc	US$ 0.4825 (-22.37%)	503.38k
ADTXAditxt Inc	US$ 0.0282 (46.88%)	168.84M
GDCGD Culture Group Ltd	US$ 0.0244 (20.20%)	124.41M
CIITTianci International Inc	US$ 0.9879 (101.61%)	23.98M
INLFINLIF Limited	US$ 0.0906 (-18.38%)	19.13M
MBRXMoleculin Biotech Inc	US$ 2.80 (-10.26%)	7.2M

銘柄コード

株価

出来高

ADTXAditxt Inc

US$ 0.0282

(46.88%)

168.84M

GDCGD Culture Group Ltd

US$ 0.0244

(20.20%)

124.41M

CIITTianci International Inc

US$ 0.9879

(101.61%)

23.98M

INLFINLIF Limited

US$ 0.0906

(-18.38%)

19.13M

MBRXMoleculin Biotech Inc

US$ 2.80

(-10.26%)

7.2M

TRIB...$1.44...🥳...No Position...Will watch for possible entry...Just noticed this News...DUBLIN, Ireland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling results from its latest pre-pivotal clinical trial for its next-generation continuous glucose monitoring (CGM) system. The pre-pivotal clinical trial, which included 30 diabetic participants—primarily individuals with Type 1 diabetes—represents a significant milestone in Trinity's mission to deliver affordable, high-performance CGM technology.

Trinity Biotech’s redesigned ergonomic modular device features a reusable applicator and a rechargeable wearable transmitter that eliminates costly disposable components while delivering a seamless user experience. By using more durable, reusable components, enabled by Trinity’s proprietary self-inserting sensor technology, the Trinity CGM is designed to deliver care at a significantly lower cost than today’s two largest manufacturers. By addressing affordability—a key barrier to adoption of this life changing technology —Trinity’s innovative approach has the potential to bring CGM technology to millions of individuals who have been priced out of the market. This disruptive design not only expands access but also redefines sustainability in the CGM space, further differentiating Trinity’s solution from current market leaders.

“We believe that our patented technology—featuring a modular, eco-friendly design and cutting-edge sensor performance—represents a paradigm shift in the CGM market, which is projected to exceed $20 billion by 2029. We are developing a CGM system that is not only highly accurate but also disruptively affordable and user-friendly,” said John Gillard, CEO of Trinity Biotech. “The two largest CGM manufacturers currently generate approximately $11 billion in sales annually serving just 10 million users combined—less than 2% of the 800 million people living with diabetes worldwide. This reflects a market which is constrained by the high cost of existing technologies. By delivering a solution that drastically reduces costs while maintaining top-tier performance, we believe we can significantly expand access to CGM devices and unlock the full potential of this underserved market.”